Intensity Therapeutics, Inc. (INTS) Reports In-Line Q3 EPS

Intensity Therapeutics, Inc. (NASDAQ: INTS) reported Q3 EPS of ($0.06), in-line with the analyst estimate of ($0.06).

For earnings history and earnings-related data on Intensity Therapeutics, Inc. (INTS) click here.

You May Also Be Interested In

• eToro Group (ETOR) Reiterated at Overweight by Cantor Fitzgerald
• Filament Health ships psilocybin drug to Phase 3 palliative care trial
• H.C. Wainwright Reiterates Buy Rating on Innate Pharma S.A. (IPHA)